Literature DB >> 31065481

Potential anticancer applications of the novel naringin-based ruthenium (II) complex.

John Phillip Garcia1, Buddolla Anantha Lakshmi1, Sanghyo Kim1.   

Abstract

Ruthenium seems to be a promising alternative to platinum because of the wide range of oxidation states it has and its ability to form complexes with bioactive ligands. In this study, naringin, a naturally occurring flavonoid, was used to synthesize a novel ruthenium complex with potential anticancer activity. The characterization of the synthesized complex was done by UV-Vis spectroscopy, FTIR and NMR studies. In addition, the complex was tested against Human A549 cell lines to determine the anticancer effect, and against human dermal fibroblasts (HDFa) to find any underlying toxicity. Further, the morphological changes of the cancer cells can be determined by using bio-atomic force microscopy. Results showed that the synthesized complex was able to induce anticancer effects against A549 with minimal impact to HDFa. In this study, we investigated the anticancer properties of naringin-ruthenium (II) complex using live- and dead-cell staining assay, MTT, Trypan blue, and lactate dehydrogenase assay. Further, morphological changes were observed in the A549 cells using Bio-AFM. The Bio-AFM results have proven the better cytotoxic behavior of naringin-ruthenium (II) complex. The cell viability results also provided the anticancer efficacy of the complex.

Entities:  

Keywords:  Bio-atomic force microscopy; Cancer A549 cell line; Flavonoid; Human dermal fibroblasts (HDFa); Ruthenium-naringin complex

Year:  2019        PMID: 31065481      PMCID: PMC6475516          DOI: 10.1007/s13205-019-1718-4

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  16 in total

1.  Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway.

Authors:  Xiaoxin Yang; Lanmei Chen; Yanan Liu; Yongguang Yang; Tianfeng Chen; Wenjie Zheng; Jie Liu; Qing-Yu He
Journal:  Biochimie       Date:  2011-07-28       Impact factor: 4.079

2.  Anticancer activity of two ruthenium(II)-DMSO-chalcone complexes: Comparison of cytotoxic, pro-apoptotic and antimetastatic potential.

Authors:  Katarina K Jovanovic; Nevenka Gligorijevic; Ruchi Gaur; Lallan Mishra; Sinisa Radulovic
Journal:  J BUON       Date:  2016 Mar-Apr       Impact factor: 2.533

Review 3.  Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action.

Authors:  M Ashraful Alam; Nusrat Subhan; M Mahbubur Rahman; Shaikh J Uddin; Hasan M Reza; Satyajit D Sarker
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

4.  Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma.

Authors:  Camila A Camargo; Maria Cristina C Gomes-Marcondes; Nathalie C Wutzki; Hiroshi Aoyama
Journal:  Anticancer Res       Date:  2012-01       Impact factor: 2.480

Review 5.  Therapeutic potential of naringin: an overview.

Authors:  Rui Chen; Qiao-Ling Qi; Meng-Ting Wang; Qi-Yan Li
Journal:  Pharm Biol       Date:  2016-08-26       Impact factor: 3.503

6.  Quercetin-Iron Complex: Synthesis, Characterization, Antioxidant, DNA Binding, DNA Cleavage, and Antibacterial Activity Studies.

Authors:  Aun Raza; Xiuquan Xu; Li Xia; Changkun Xia; Jian Tang; Zhen Ouyang
Journal:  J Fluoresc       Date:  2016-08-01       Impact factor: 2.217

7.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

8.  Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NF‑κB/COX‑2‑caspase-1 pathway in HeLa cervical cancer cells.

Authors:  Lan Zeng; Yulan Zhen; Yiming Chen; Lin Zou; Ying Zhang; Fen Hu; Jianqiang Feng; Jianhua Shen; Bing Wei
Journal:  Int J Oncol       Date:  2014-08-22       Impact factor: 5.650

9.  Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway.

Authors:  Hongzhong Li; Bing Yang; Jing Huang; Tingxiu Xiang; Xuedong Yin; Jingyuan Wan; Fuling Luo; Li Zhang; Hongyuan Li; Guosheng Ren
Journal:  Toxicol Lett       Date:  2013-05-18       Impact factor: 4.372

Review 10.  Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors.

Authors:  Prakash Thangavel; Buddolla Viswanath; Sanghyo Kim
Journal:  Int J Nanomedicine       Date:  2017-04-04
View more
  2 in total

1.  Synthesis and Cytotoxicity Studies on Ru and Rh Nanoparticles as Potential X-Ray Fluorescence Computed Tomography (XFCT) Contrast Agents.

Authors:  Yuyang Li; Kian Shaker; Martin Svenda; Carmen Vogt; Hans M Hertz; Muhammet S Toprak
Journal:  Nanomaterials (Basel)       Date:  2020-02-12       Impact factor: 5.076

2.  A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies.

Authors:  Maryam Ghanbari-Movahed; Gloria Jackson; Mohammad Hosein Farzaei; Anupam Bishayee
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.